000			02230 a2200673 4500
005			20250517092716.0
264		0	_c20171227
008			201712s 0 0 eng d
022			_a1569-8041
024	7		_a10.1093/annonc/mdw174 _2doi
040			_aNLM _beng _cNLM
100	1		_aChatterjee, M
245	0	0	_aSystematic evaluation of pembrolizumab dosing in patients with advanced non-small-cell lung cancer. _h[electronic resource]
260			_bAnnals of oncology : official journal of the European Society for Medical Oncology _c07 2016
300			_a1291-8 p. _bdigital
500			_aPublication Type: Clinical Trial, Phase I; Journal Article; Randomized Controlled Trial
650	0	4	_aAdult
650	0	4	_aAged
650	0	4	_aAntibodies, Monoclonal _xadministration & dosage
650	0	4	_aAntibodies, Monoclonal, Humanized _xadministration & dosage
650	0	4	_aB7-H1 Antigen _xgenetics
650	0	4	_aCarcinoma, Non-Small-Cell Lung _xdrug therapy
650	0	4	_aDisease-Free Survival
650	0	4	_aDose-Response Relationship, Drug
650	0	4	_aDrug-Related Side Effects and Adverse Reactions _xpathology
650	0	4	_aErbB Receptors _xgenetics
650	0	4	_aFemale
650	0	4	_aGene Expression Regulation, Neoplastic _xdrug effects
650	0	4	_aHumans
650	0	4	_aMale
650	0	4	_aMiddle Aged
650	0	4	_aNeoplasm Staging
650	0	4	_aPrognosis
650	0	4	_aTreatment Outcome
700	1		_aTurner, D C
700	1		_aFelip, E
700	1		_aLena, H
700	1		_aCappuzzo, F
700	1		_aHorn, L
700	1		_aGaron, E B
700	1		_aHui, R
700	1		_aArkenau, H-T
700	1		_aGubens, M A
700	1		_aHellmann, M D
700	1		_aDong, D
700	1		_aLi, C
700	1		_aMayawala, K
700	1		_aFreshwater, T
700	1		_aAhamadi, M
700	1		_aStone, J
700	1		_aLubiniecki, G M
700	1		_aZhang, J
700	1		_aIm, E
700	1		_aDe Alwis, D P
700	1		_aKondic, A G
700	1		_aFløtten, Ø
773	0		_tAnnals of oncology : official journal of the European Society for Medical Oncology _gvol. 27 _gno. 7 _gp. 1291-8
856	4	0	_uhttps://doi.org/10.1093/annonc/mdw174 _zAvailable from publisher's website
999			_c25961795 _d25961795